Bioventus elects Mary Kay Ladone to Board as Class II director effective July 15, 2021

Bioventus Inc.

Mary Kay Ladone appointed to Board, Audit and Risk Committee, and Compensation Committee.
Ladone is SVP, Corporate Development, Strategy and IR at Hill-Rom, with prior roles at Baxalta and Baxter.
Annual cash retainer $55,000 plus $10,000 for Audit and $7,500 for Compensation Committee service.
Initial restricted stock unit award with aggregate fair value of $152,000, pro-rated per policy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mary Kay Ladone

Class II Director

BVS · Bioventus Inc.

Effective: 2021-07-15
Filed: July 14, 2021, 7:59 PM ET

On July 12, 2021, the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) elected Mary Kay Ladone to the Board as a Class II director for a term ending at the 2023 annual meeting of stockholders of the Company, effective July 15, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mary Kay Ladone was elected as Class II Director at Bioventus Inc..

Action: elected
Role: Class II Director

Exact text from the filing

On July 12, 2021, the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) elected Mary Kay Ladone to the Board as a Class II director for a term ending at the 2023 annual meeting of stockholders of the Company, effective July 15, 2021

View on SEC.gov

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001628280-21-013829

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.